These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 31125586)

  • 1. Targeting Nuclear Receptors with PROTAC degraders.
    Flanagan JJ; Neklesa TK
    Mol Cell Endocrinol; 2019 Aug; 493():110452. PubMed ID: 31125586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosteric small molecule modulators of nuclear receptors.
    Meijer FA; Leijten-van de Gevel IA; de Vries RMJM; Brunsveld L
    Mol Cell Endocrinol; 2019 Apr; 485():20-34. PubMed ID: 30703487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.
    Han X; Zhao L; Xiang W; Qin C; Miao B; Xu T; Wang M; Yang CY; Chinnaswamy K; Stuckey J; Wang S
    J Med Chem; 2019 Dec; 62(24):11218-11231. PubMed ID: 31804827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noncanonical mechanisms to regulate nuclear receptor signaling.
    Sadana P
    Future Med Chem; 2012 Jun; 4(10):1307-33. PubMed ID: 22800372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orphan nuclear receptors as drug targets for the treatment of prostate and breast cancers.
    Roshan-Moniri M; Hsing M; Butler MS; Cherkasov A; Rennie PS
    Cancer Treat Rev; 2014 Dec; 40(10):1137-52. PubMed ID: 25455729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of nuclear receptor function: Targeting the protein-DNA interface.
    Veras Ribeiro Filho H; Tambones IL; Mariano Gonçalves Dias M; Bernardi Videira N; Bruder M; Amorim Amato A; Migliorini Figueira AC
    Mol Cell Endocrinol; 2019 Mar; 484():1-14. PubMed ID: 30703486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Nuclear Receptors in Prostate Cancer.
    Shiota M; Fujimoto N; Kashiwagi E; Eto M
    Cells; 2019 Jun; 8(6):. PubMed ID: 31212954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformational adaptation of nuclear receptor ligand binding domains to agonists: potential for novel approaches to ligand design.
    Togashi M; Borngraeber S; Sandler B; Fletterick RJ; Webb P; Baxter JD
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):127-37. PubMed ID: 15860255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationship of nuclear receptor-ligand interactions.
    Greschik H; Moras D
    Curr Top Med Chem; 2003; 3(14):1573-99. PubMed ID: 14683516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PROTACs: New method to degrade transcription regulating proteins.
    Hu B; Zhou Y; Sun D; Yang Y; Liu Y; Li X; Li H; Chen L
    Eur J Med Chem; 2020 Dec; 207():112698. PubMed ID: 32858471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges.
    Zeng S; Huang W; Zheng X; Liyan Cheng ; Zhang Z; Wang J; Shen Z
    Eur J Med Chem; 2021 Jan; 210():112981. PubMed ID: 33160761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-canonical modulators of nuclear receptors.
    Tice CM; Zheng YJ
    Bioorg Med Chem Lett; 2016 Sep; 26(17):4157-64. PubMed ID: 27503683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The functional significance of nuclear receptor acetylation.
    Popov VM; Wang C; Shirley LA; Rosenberg A; Li S; Nevalainen M; Fu M; Pestell RG
    Steroids; 2007 Feb; 72(2):221-30. PubMed ID: 17291555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of new non-steroidal farnesoid X receptor modulators through 3D shape similarity search and structure-based virtual screening.
    Wang L; Si P; Sheng Y; Chen Y; Wan P; Shen X; Tang Y; Chen L; Li W
    Chem Biol Drug Des; 2015 Apr; 85(4):481-7. PubMed ID: 25228339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications.
    Bourguet W; Germain P; Gronemeyer H
    Trends Pharmacol Sci; 2000 Oct; 21(10):381-8. PubMed ID: 11050318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noncoding RNAs and the control of signalling via nuclear receptor regulation in health and disease.
    Cathcart P; Lucchesi W; Ottaviani S; De Giorgio A; Krell J; Stebbing J; Castellano L
    Best Pract Res Clin Endocrinol Metab; 2015 Aug; 29(4):529-43. PubMed ID: 26303081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classical nuclear hormone receptor activity as a mediator of complex biological responses: a look at health and disease.
    Yen PM
    Best Pract Res Clin Endocrinol Metab; 2015 Aug; 29(4):517-28. PubMed ID: 26303080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation functions 1 and 2 of nuclear receptors: molecular strategies for transcriptional activation.
    Wärnmark A; Treuter E; Wright AP; Gustafsson JA
    Mol Endocrinol; 2003 Oct; 17(10):1901-9. PubMed ID: 12893880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear hormone receptor co-repressors.
    Baniahmad A
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):89-97. PubMed ID: 15860250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial for Special Issue on "Alternative nuclear receptor ligands".
    Moore TW; Frasor J
    Mol Cell Endocrinol; 2019 Aug; 493():110479. PubMed ID: 31173820
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.